title: Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'.
authors.affiliation: Unit of MedicalOncology 2, Azienda Ospedaliero-Universitaria Pisana, via Roma 57, 56126 Pisa, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Schirripa
authors.forename: F
authors.initials: F
authors.lastname: Loupakis
authors.forename: L
authors.initials: L
authors.lastname: Pollina
authors.forename: C
authors.initials: C
authors.lastname: Cremolini
authors.forename: G
authors.initials: G
authors.lastname: Pasquini
authors.forename: A
authors.initials: A
authors.lastname: Falcone
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized